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A decrease in renal phosphate reabsorption with mild
hypophosphatemia (phosphate leak) is found in some
hypercalciuric stone-formers. The NPT2a gene encodes a
sodium-phosphate cotransporter, located in the proximal
tubule, responsible for reclaiming most of the filtered
phosphate load in a rate-limiting manner. To determine
whether genetic variation of the NPT2a gene is associated
with phosphate leak and hypercalciuria in a cohort of 98
pedigrees with multiple hypercalciuric stone-formers, we
sequenced the entire cDNA coding region of 28 probands,
whose tubular reabsorption of phosphate normalized for the
glomerular filtration rate (TmP/GFR) was 0.7 mmol/l or lower.
We performed genotype/phenotype correlations for each
genetic variant in the entire cohort and expressed NPT2a
variant RNAs in Xenopus laevis oocytes to test for
cotransporter functionality. We identified several variants in
the coding region including an in-frame 21 bp deletion
truncating the N-terminal cytoplasmic tail of the protein
(91del7), as well as other single-nucleotide polymorphisms
that were non-synonymous (A133V and H568Y) or
synonymous. Levels of TmP/GFR and urine calcium excretion
were similar in heterozygote carriers of NPT2a variants
compared to the wild-type (wt) homozygotes. The transport
activity of the H568Y mutants was identical to the wt,
whereas the N-terminal-truncated version and the 91del7
and A133V mutants presented minor kinetic changes and a
reduction in the expression level. Although genetic variants
of NPT2a are not rare, they do not seem to be associated with
clinically significant renal phosphate or calcium handling
anomalies in a large cohort of hypercalciuric stone-forming
pedigrees.
Kidney International (2006) 69, 2261–2267. doi:10.1038/sj.ki.5000437;
published online 10 May 2006
KEYWORDS: phosphaturia; hypercalciuria; NPT2a; SLC34A1; nephrolithiasis;
polymorphisms
Idiopathic hypercalciuria is the most frequent metabolic
disorder associated with calcium nephrolithiasis.1,2 Family-
based,1,3,4 twin5 and case–control6 studies suggest that urine
calcium excretion is a heritable trait. Idiopathic hypercalciur-
ia is usually associated with increased intestinal calcium
absorption and a subset of patients has a primary mild
phosphaturic state, or ‘phosphate leak’.2,7 This results in a
compensatory increase in 1,25(OH)2D3 production and
higher intestinal phosphate as well as calcium absorption
and excretion. The combined phosphaturic and hypercalciu-
ric state favors the crystallization of calcium phosphate salts
that later grow into concretions.
Phosphate wasting with nephrolithiasis occurs in several
Mendelian traits including Dent disease8 and hereditary
hypophosphatemic rickets with hypercalciuria.9 NPT2a
encodes the rate-limiting proximal tubule sodium phosphate
cotransporter (reviewed by Murer et al.10) and is thus a
candidate gene for hereditary renal phosphaturia. A previous
study has associated NPT2a variants with phosphate leak in
two of 20 subjects, with either osteoporosis or recurrent
nephrolithiasis,11 possibly through dominant-negative ef-
fects. However, this study had several limitations and was
recently criticized.12 First, although NPT2a variants were
suggested to be functional by demonstration of decreased
phosphate currents and sodium-dependent phosphate uptake
in vitro (including when coexpressed with the wild type
(wt)), the currents were rather small. Second, as the pedigrees
were not sampled, there was no segregation analysis of
NPT2a variants or a population association study to confirm
that other carriers had abnormal renal phosphate handling.
Finally, there was no attempt made to determine the
population prevalence of mutant NPT2a in a cohort of stone
formers or osteoporotic subjects.
To determine whether genetic variants of NPT2a cause
renal phosphate handling anomalies in a large cohort of
families with multiple and recurrent stone-forming subjects,
we sequenced the entire coding region of NPT2a in siblings
with a low tubular reabsorption of phosphate normalized for
the glomerular filtration rate (TmP/GFR). We further
evaluated the association between genetic variants and
TmP/GFR by genotyping extended pedigrees. We also
conducted electrophysiological studies of NPT2a variants in
Xenopus laevis oocytes. Our findings demonstrate that
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NPT2a variants are neither rare nor responsible for renal
phosphate leak in the population tested.
RESULTS
Sequencing and genotyping
We identified a total of five polymorphisms, of which three
were non-synonymous variants (Table 1 and Figures 1 and 2)
in three different probands. These included a 21 bp in-frame
deletion (91del7) in the 50-end corresponding to amino acids
91–97 (VPKLRQA) in the N-terminal intracellular segment.
The deletion polymorphism was identified in all three
subjects by sequencing after polymerase chain reaction
(PCR) amplification of the appropriate region and subclon-
ing into the pCR2.1 vector (Stratagene, La Jolla, CA, USA).
Restriction enzyme digestion with BglI also allowed the
identification of carriers of the deletion polymorphism
(Figure 1d). The H568Y variant in exon 13 was also
confirmed by subcloning and detection with KpnI digestion
(Figure 2b). It was present in the same clones, that is, on the
same haplotype as the 91del7 deletion. The A133V variant
was found in a single proband.
Phenotypes in extended pedigrees
We used BglI digestion to identify carriers of the deletion in
extended pedigrees and compared phenotypes. As shown in
Table 2, TmP/GFR, serum phosphate levels, urine calcium
Table 1 | Genetic variants of NPT2a identified in 28
stone-formers with low TmP/GFR (less than 0.7 mmol/l)
Exon Polymorphism Number of chromosomes
4 91del7 21 bp in-frame deletion
GTCCCCAAGCTGCGCCAGGCT
352–372 of cDNA
3
5 C479T (A133V) 1
7 T855C (conserved) 13
13 C1783T (H568Y) 5
30 UTR G2180A 1
bp, base pair; TmP/GFR, tubular reabsorption of phosphate normalized for the
glomerular filtration rate; UTR, untranslated region.
E S R L V P K L R Q A G A M
Deleted sequence
Tandem sequence
E S R L G A M L MPVKL L
Re-arranged tandem sequence
? ? ? ? G A M L MPVKL L
Double sequence in heterozygote
A
A A A A A A AA
A CC C CCCC C C C C C C CCA AA A AG
G G G G G G G G G G G G G G G
G G G G G G G G G G GG GGT
C C C C C C C C C CN NT
A A A A AA A AG G G G G G G G G G G G G G GCC C C C C C C C C C CT T T T T T T T
T T T T T T T
T T T T T
a d
b
c
W/D W/W
Bg1I digestion of the
deletion polymorphism
Figure 1 | NPT2a gene sequencing of exon 4. (a) Wt sequence of exon 4 showing position of the 21 bp deletion and flanking tandem repeat
sequences responsible for strand slippage. (b) Sequence of a heterozygote carrier of the deletion mutant showing double sequence at the start
of the deletion. (c) Sequencing of the cloned NPT2a deletion variant. (d) BglI digestion of the deletion polymorphism in a W/91del7
heterozygote and wt homozygote.
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excretion, and number of stone episodes were similar in
heterozygotes compared to wt homozygotes. Serum para-
thyroid hormone levels were marginally higher in hetero-
zygotes.
Population screening of the NPT2a variants
To determine whether NPT2a variants are present in an
unselected population, we screened 96 anonymous DNA
samples by PCR from a Caucasian North American
population and identified six heterozygotes for the deletion,
three of which were also heterozygous for H568Y (data
not shown). We identified one subject with the H568Y
variant only.
Expression of NPT2a in X. laevis oocytes
Wt NPT2a was expressed in Xenopus oocytes as were four
different variants (the A133V, the N-terminal deletion 91del7,
H568Y, and 91del7-H568Y, which contains both variants).
Examples of currents recorded in the presence of Barth’s
solution and after addition of 1 mM Pi are shown in Figure
3a. The inorganic phosphate (Pi)-dependent current–voltage
relationship (Figure 3b) is roughly linear and non-injected
oocytes were completely insensitive to Pi addition, in
agreement with previous observations.13 At 50 mV, Pi-
induced currents through the different NPT2a proteins are
shown in Figure 3c. There was no difference between the
levels of transport mediated through wt NPT2a and the
H568Y mutant, but lower levels of current were observed for
the A133V mutants (Po0.05) and for the 91del7 and 91del7-
H568Y mutants (Po0.001).
A Pi concentration of 1 mM corresponds to a saturating
concentration for the wt cotransporter as its reported affinity
constant at pH 7.4 is 0.11 mM.12 Pi affinity constants, roughly
estimated by comparing the currents stimulated by the
addition of 0.1 and 1 mM Pi, were always between 0.05 and
0.10 mM for A133V, 91del7, H568Y, and 91del7-H568Y, and
were not significantly different from the wt affinity constants
(data not shown). Consequently, the observed reduction in
the Pi-dependent currents for A133V, 91del7, and 91del7-
H568Y could not be owing to a large increase in the Pi
affinity constant and it must either be owing to a reduced
turnover rate of A133V, 91del7, and 91del7-H568Y or to a
reduction in the number of expressed cotransporters.
Discrimination between these two possibilities was possible
by examining transient currents expressed by these proteins.
Transient (or presteady-state) currents are thought to
reflect the presence of mobile charges, associated with each
cotransporter, which move within the membrane electrical
field.14,15 These currents can be modelled by a Boltzmann
equation from which three characteristic parameters were
extracted: Qmax, V0.5, and z. Qmax is the total mobile charge,
V0.5 is the membrane potential at which the mobile charge is
equilibrated between the inward and outward facing config-
uration, and z is the equivalent valence of a charge that moves
across the entire membrane electric field.
a
b
Wild type H568Y heterozygote
KpnI digestion of
the H568Y polymorphism
W/W
C
T
G H L G Y L
H
A A A A A A A A A AG GG G GG G G G GG G G G G G GG G GGGT T T T T T T TC C C C C C C C C C C C C C C C C C C
W/H568Y
Figure 2 | NPT2a gene sequencing of exon 13. (a) NPT2a gene
sequencing of exon 13 showing the wt sequence and a heterozygote
H568Y carrier. (b) KpnI digestion of a wt homozygote and W/ H568Y
heterozygote.
Table 2 | Genotype–phenotype correlations for the 91del7 NPT2a gene variant in 722 siblings from 98 families
W/W W/91del7a
Males (303) Females (348) Males (36) Females (35) P-value
Age 52.2714.2 53.2714.4 50.7710.9 47.9715.0 0.54
Stone-formers (%) 192 (63.4) 165 (47.4) 24 (66.7) 15 (42.9) 0.99
SPO4 (mmol/l) 1.0670.24 1.1370.25 1.0270.18 1.0970.16 0.25
b
TmP/GFR (mmol/l) 0.8170.25 0.9070.29 0.7770.21 0.8870.14 0.35b
UCaV (mmol/day) 6.873.0 5.272.3 8.374.8 5.372.0 0.11
UCaV/kg (mmol/kg/day) 0.0970.04 0.0870.04 0.1070.05 0.0870.04 0.11
SCa (mmol/l) 2.3470.10 2.3370.09 2.3670.11 2.3570.10 0.05
PTH (pmol/l) 3.7872.39 3.6872.25 3.3171.53 2.9571.21 0.03
PTH, parathyroid hormone; SCa, serum calcium; SPO, serum phosphate; TmP/GFR, tubular reabsorption of phosphate normalized for the glomerular filtration rate.
All values mean7s.d.
aIncludes subjects with haplotype 91del7/H568Y.
bP-values corrected for gender.
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In Figure 4a, examples of transient currents are shown
where the membrane voltage is returned to 50 mV from
potentials ranging from 150 to þ 50 mV. Under our
experimental conditions, 99% of a 100 mV pulse is achieved
within 2 ms and most of the large capacitive current can be
eliminated by considering the transient current remaining
after this initial period. These transient currents are not
present in non-injected oocytes and vanish in the presence of
a saturating Pi concentration (Figure 4a). In Figure 4b,
normalized Q is displayed as a function of the conditioning
membrane potential for the wt cotransporter and for the
91del7-H568Y and the A133V mutants. The valence of the
mobile charge associated with NPT2a did not change
significantly between the wt (0.67), A133V (0.76), 91del7
(0.67), H568Y (0.72), and 91del7-H568Y (0.70). This is
consistent with previous findings for wt NPT2a and for a few
NPT2a mutants.16 In contrast, a small but significant
negative shift in V0.5 was observed for the 91del7-H568Y
mutant (Po0.05) (see Figure 4b), whereas the V0.5 values for
the A133V was observed to be about 20 mV more positive
than for the wt (Po0.01) (see Figure 4b).
Qmax correlated closely with the steady-state current owing
to the addition of 1 mM Pi (Figure 4c). Qmax averaged
10.171.2 and 8.671.0 nC for the wt and H568Y, whereas it
was reduced to 8.170.8 nC for A133V, to 5.170.7 nC for
91del7, and to 5.670.7 nC for 91del7-H568Y. In the absence
of a significant change in the ‘z’-value, this is consistent
with the simple interpretation that V133C, 91del7, and
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Figure 3 | Phosphate-induced current in X. laevis oocytes injected
with wt or variant NPT2a cRNA. (a) Examples of currents recorded
in the absence or in the presence of 1 mM HPO4
2. The I–V curves
obtained from these currents are presented in (b) together with
Pi-induced current obtained by subtracting one current from the
other. (c) The normalized Pi-induced current at 50 mV (7s.e.m.)
for the four variants (H568Y, A133V, 91del7, and 91del7-H568Y)
with respect to the wt Na/Pi cotransporter (n¼ 16–18 oocytes from
three to five different donors for each column). The currents were
found significantly lower than for wt cotransporters in the case of
A133V (* or Po0.05) and in the case of 91del7 and 91del7-H568Y
(*** or Po0.05).
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Figure 4 | Transient currents recorded from the NPT2a
cotransporter. (a) An example of transient currents from an oocyte
expressing the wt NPT2a cotransporter. These tail currents were
recorded 2 ms after return of the membrane potential to 50 mV
from various potentials ranging from 150 to þ 50 mV. It is evident
that the presence of 1 mM Pi greatly inhibits these transient currents.
The charge transferred is obtained from the area under the current
traces and the portion specifically related to the cotransporter can be
obtained by subtraction of the residual charge observed in the
presence of Pi. In (b), this is performed for typical oocytes expressing
the wt cotransporter, the A133V mutant and the 91del7-H568Y
mutant. The Q vs V curves are fitted with the Boltzman equation and
normalized to the maximal charge. The V0.5 values for the H568Y
mutant (5573 mV, n¼ 13) and the 91del7 mutant (6572 mV,
n¼ 11) were not found to be statistically different from the V0.5 value
of the wt cotransporter (5973 mV, n¼ 25). In contrast, the V0.5
values of the 91del7-H568Y mutant (6873 mV, n¼ 14) for the
A133V mutant (4174 mV, n¼ 14) (were found to be significantly
different from the wt V0.5 (Po0.05, and Po0.01, respectively). In
(c), the correlation between the steady-state Pi-induced current
(1 mM HPO4
2) and the maximal charge transferred is shown for the
(’) wt NPT2a and the (&) four variants.
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91del7-H568Y display a lower Pi-induced current because
their expression levels are lower compared with the wt and
the H568Y mutant.
Expression of NPT2a in kidney cells
As shown in Figure 5, enhanced green fluorescent protein
(EGFP)-tagged NPT2a variants were properly expressed
when transfected in OK cells, a cell line with proximal
tubular characteristics. The accumulation of cotransporters
could be seen as dots in the cytoplasm and near the plasma
membrane surface. Expression levels estimated by Western
blotting were similar (data not shown).
DISCUSSION
This study demonstrates that, in a large cohort of
hypercalciuric pedigrees ascertained for the presence of
multiple kidney stone formers, genetic polymorphisms at
the NPT2a locus are not associated with variation in renal
phosphate handling. We carefully selected index cases with
decreased renal phosphate reabsorption and sequenced the
entire coding region of the NPT2a gene. We identified several
variants, one of which leads to a 7-amino-acid deletion in the
N-terminal region of the transporter (91del7). When
extended pedigrees were examined, there were no differences
in serum phosphate, TmP/GFR, or urine calcium excretion
between carriers and non-carriers of genetic variants. In
addition, these variants were identified in a random
population. However, we did not find 91del7 homozygotes,
which could potentially present with a clinical phenotype of
mild phosphate wasting. Heterologous expression in X. laevis
oocytes demonstrated similar phosphate transport character-
istics for the NPT2a variants. It remains to be determined
whether the lower expression levels observed for variants
containing 91del7 and A133V have any implication for their
in vivo expression. Incidentally, we subsequently found that
the deletion variant and exon 13 substitution have been
described by a human complementary DNA sequencing
consortium17 as ‘highly similar to NPT2’ (GI Accession
number: 21755493). Therefore, our results confirm that those
are NPT2a genetic variants and not splicing variants or
distinct NPT2a isoforms.
The 91del7 deletion located in the N-terminus probably
arose from DNA strand slippage. This would have occurred
by pairing between direct repeats of homologous sequences
of 5 bp18,19 that flank the deletion (Figure 1). The role
of the intracellular N-terminal region of NPT2a is unknown
and measurable consequences of the 91del7 and A133V
variants were examined clinically and for functional
transport or expression consequences in vitro. Although
these genetic variants of NPT2a are not rare, they do not
lead to significant phenotypic differences either in vivo or
in vitro. In addition, it is unlikely that other functional
NPT2a variants are frequently associated with renal phos-
phate handling anomalies in hypercalciuric stone-formers, at
least in our population. We speculate that other genetic
variants such as identified by Prie´ et al.11 are rare.
Furthermore, the functionality of such variants has been
questioned as in vitro findings in this study were not
subsequently confirmed.12
It has been suggested that serum phosphate and, possibly,
renal phosphate handling are genetically determined.5 The
NPT2a gene is a legitimate candidate as it encodes the apical
membrane sodium phosphate cotransporter located in
proximal tubules. In mice, targeted disruption of the NPT2
gene (Npt2/) leads to hypophosphatemic rickets,20 and
although heterozygous Npt2þ / mice have a normal serum
phosphate concentration, renal phosphate excretion is
significantly increased compared with wt mice. These
characteristics resemble those found in the subjects selected
in our study. Finally, no mutations in NPT2a were found in a
large Bedouin pedigree or in four other small families
with hereditary hypophosphatemic rickets with hyper-
calciuria.21 Other disorders associated with phosphaturia
include hypophosphatemic rickets owing to mutations in
PHEX and FGF23. These diseases are not associated
with nephrolithiasis and phosphaturia is thought to result
from decreased protein expression and insertion of NPT2
in the brush-border membrane. NHERF-1, encoding a
protein adapter that participates in the hormone-induced
internalization of NPT2, is another potential candidate as
mice in which this gene was deleted exhibit renal phosphate
wasting with hypercalciuria.22 However, renal phosphate
excretion does not seem to correlate with urine calcium
excretion.23
In contrast to simple Mendelian disorders, the identifica-
tion of genes causing complex traits such as idiopathic
hypercalciuria represents a formidable challenge. Performing
candidate gene studies in subgroups of patients with
particular phenotypes such as mild phosphate wasting is a
more targeted approach with a higher potential yield for gene
discovery. We have previously excluded several candidate
genes using this approach.24–26 However, a more global
approach will eventually be required. For example, the
identification of common variants of proteins whose function
is known, by projects such as the HapMap initiative,27 will
facilitate gene discovery for complex traits.
In conclusion, in vivo and in vitro studies do not support a
role for NPT2a gene variation in ‘phosphate leak’ associated
with calcium nephrolithiasis.
WT 91del7 A133V
Figure 5 | Expression of wt and mutant cotransporters in OK cells.
Cells were transfected with the EGFP-fused wt and mutant
cotransporters and processed for deconvolution fluorescence
microscopy.
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MATERIALS AND METHODS
Families and probands
This study was approved by institutional review committees, and
informed consent was obtained from all participants. A complete
description of the study design has been published.1 From
September 1995 to February 2004, we recruited families of
French-Canadian descent from specialized stone clinics and
lithotripsy units. These clinics ascertain approximately 1000 patients
annually. Questionnaires were systematically handed to probands.
Subjects with at least one episode of urolithiasis of predominant
calcium content, as determined by crystallographic analysis (Louis C
Herring & Co., Orlando, FL, USA), and a positive family history in a
sibling, were interviewed by a clinical research nurse and asked to
contact affected and unaffected siblings. Families with at least two
affected sibs were followed up. Thereafter, all consenting affected
siblings from the same sibship were interviewed and phenotyped on
the same day and place, on an outpatient basis. Urine sampling
consisted of 24-h urine collection under free dietary conditions as
well as a fasting morning void. Serum was also obtained for
biochemical analyses. We attempted to recruit all affected subjects,
but elected to ascertain up to two unaffected sibs per sibship.
Affected siblings had at least one stone episode verified by
crystallographic analysis or by an imaging method consisting in
intravenous pyelogram or abdominal ultrasound. Siblings with no
stone passage but with an imaging method showing a stone were
also considered affected. Episodes and onset age of urolithiasis for
sibs and probands were confirmed by a detailed review of all records
available from the respective hospitals where clinical assessments
were made. Siblings with medical conditions predisposing to
urolithiasis (hyperparathyroidism, inflammatory bowel disease,
chronic diarrhea, urinary tract infection before stone episodes) or
on medications susceptible to modify urine composition (diuretics,
calcium, and vitamin supplements) were not included in the study.
A total of 98 hypercalciuric pedigrees were included in the study
comprising 722 relatives. From those, we selected 28 stone-forming
sibs with a threshold for phosphate reabsorption (TmP/GFR) of
0.7 mmol/l or lower. Clinical characteristics of the cohort and the 28
index cases are shown in Tables 3 and 4, respectively.
Sequencing of the NPT2a gene
We used intronic primers to amplify all 13 exons of the NPT2a gene
from the 28 index cases (sequences available upon request).
Amplification was performed for 35 cycles using standard PCR
methods. The PCR products were sequenced using a commercially
available kit (BigDye Terminator 3.0 Cycle Sequencing Kit from
Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 3100
automated sequencer (Applied Biosystems). Both DNA strands were
sequenced and analyzed using the appropriate software (Applied
Biosystems). Sequence alignments were performed with bl2seq
(http://www.ncbi.nlm.nih.gov/BLAST) and CLUSTALW (http://bio
web.pasteur.fr) online software.
When possible, restriction enzyme digestion of amplified
genomic DNA was used for subsequent confirmation or identifica-
tion of individual genotypes.
Expression of NPT2a in X. laevis oocytes
In vitro transport characteristics of the genetic variants identified in
three families were analyzed by expressing the mutated RNA in X.
laevis oocytes. Wt complementary DNA encoding human NPT2a
(kindly provided by Drs J Biber and H Mu¨rer, Physiology Institute,
University of Zurich, Zurich, Switzerland) was introduced into the
transcription vector pSP64T between the XhoI and NotI sites.
Specific genetic variants were introduced into the wt cDNA using a
commercially available kit (Stratagene), and confirmed by dideoxy
sequencing. Capped mRNA was synthesized in vitro using the
mMessage mMachine kit (Ambion, Austin, TX, USA) with SP6 RNA
polymerase. Purified RNA was quantified by absorption at 260 nm,
and the quality was verified by calculating the ratio of readings at
260 and 280 nm (A260/A280). Preparation of defolliculated X. laevis
oocytes (stages V or VI) was performed as described previously.28,29
For wt or variant NPT2a mRNA expression, oocytes were injected
with 46 nl of solution containing 0.1 mg/ml of mRNA in water. They
Table 3 | Clinical data for 722 siblings from 98 stone-forming and hypercalciuric pedigrees
Males Females
Non-stone
forming (109)
Stone
forming (215) P-value
Non-stone
forming (178)
Stone
forming (180) P-value
Total
P-value
Age 53.4715.0 51.2713.1 0.16 54.5714.2 50.7713.8 0.01 0.004
Stone episodes (no.) — 7.7720 — — 3.975.7 — —
SPO4 (mmol/l) 1.0970.25 1.0470.23 0.06 1.1470.18 1.1070.29 0.09 0.01
a
TmP/GFR (mmol/l) 0.8470.28 0.7970.24 0.10 0.9170.26 0.8770.30 0.20 0.01a
UCaV (mmol/day) 5.7572.4 7.573.5 o103 4.772.1 5.772.4 0.004 o105
UCaV/kg (mmol/kg/day) 0.0770.03 0.1070.04 o103 0.0870.04 0.0970.04 0.03 o105
SCa (mmol/l) 2.3470.10 2.3370.11 0.85 2.3470.09 2.3370.09 0.32 0.54
PTH (pmol/l) 3.4371.16 3.8772.56 0.075 3.7672.49 3.3771.69 0.10 0.93
PTH, parathyroid hormone; SCa, serum calcium; SPO, serum phosphate; TmP/GFR, tubular reabsorption of phosphate normalized for the glomerular filtration rate; UCaV, 24-h
urine calcium excretion.
All values mean7s.d.
aCorrected for gender.
Table 4 | Clinical characteristics for 28 stone-formers selected
for low TmP/GFR (less than 0.7 mmol/l)
Males (19) Females (9)
Age (years) 54.5711.5 47.3711.3
Stone episodes (no.) 18745 5.373.6
Serum PO4 (mmol/l) 0.7270.07 0.7670.07
TmP/GFR (mmol/l) 0.4870.11 0.5170.12
24-h UCaV (mmol/day) 5.8473.12 4.5572.01
24-h UCaV/kg (mmol/kg/day) 0.07170.041 0.06970.030
Serum Ca (mmol/l) 2.2870.10 2.2870.09
PTH (pmol/l) 4.2372.37 4.8172.32
PTH, parathyroid hormone; SCa, serum calcium; SPO, serum phosphate; TmP/GFR,
tubular reabsorption of phosphate normalized for the glomerular filtration rate;
UCaV, 24-h urine calcium excretion.
All values mean7s.d.
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were then incubated for 4–7 days at 181C in Barth’s solution (in mM:
90 NaCl, 3 KCl, 0.82 MgSO4, 0.41 CaCl2, 0.33 Ca(NO3)2, 5 HEPES,
pH 7.6) supplemented with 5% horse serum, 2.5 mM Naþ -pyruvate,
100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.1 mg/ml kana-
mycin.
Na/Pi cotransporter activity was assessed using the two-electrode
voltage clamp technique29,30 in the presence of a bathing medium
(control solution) containing (in mM): 90 NaCl, 3 KCl, 0.82 MgCl2,
0.74 CaCl2, 10 mM HEPES, pH adjusted to 7.4 with tris[hydroxy-
methyl]aminomethane. When needed, 1 or 0.1 mM HPO4
2 was
added to the bathing solution using a stock solution containing
200 mM KH2PO4 and 800 mM K2HPO4 at pH 7.44 to obtain the Pi-
sensitive steady-state current. Presteady-state currents (the transient
currents that persisted after all capacitive currents have vanished,
B2 ms after the onset of a voltage pulse) were also recorded. These
currents reflect the charge movement associated with the voltage-
dependent conformational changes of the cotransporter,14,15 which
may represent the displacement of the Na binding site across the
membrane electrical field.
Expression of NPT2a variants in opossum kidney cells
The wt and mutant NPT2a full-length cDNAs previously cloned in
the pSPORT vector were amplified by PCR with primers containing
the XhoI or SacII restriction sites for insertion in the pEGFP-C1
plasmid in-frame with EGFP. OK cells were cultured on tissue
culture coverslips in 35 mm Petri dishes in minimum essential
medium (Invitrogen, Burlington, ON, Canada) containing 10% fetal
bovine serum. At about 80% confluence, cells were transfected with
2 mg of the EGFP–NPT2a constructs using 10 ml of Lipofectamine
2000 (Invitrogen) in a total volume of 500 ml/well of Opti-minimum
essential medium I medium (Invitrogen). After 4 h, the transfection
medium was replaced with minimum essential medium.
The coverslips were removed 48 h after transfection from the
culture dishes and placed in 4% paraformaldehyde for 30 min to fix
the cells. The coverslips were then washed five times in phosphate-
buffered saline, and placed face down on a microscope slide on a drop
of Vectashield mounting medium containing DAPI (40,6-diamidine-
20-phenylindole dihydrochloride) (Vector Laboratories, Burlington,
ON, Canada) to stain the nuclei. The coverslips were sealed with nail
polish, and the cells were observed for fluorescence within 4 h. The
cells were photographed on a Leica DMR fluorescence microscope
using filters for DAPI and EGFP, and the two images were combined
using the OpenLab3.1.1 program (Improvision).
Statistical analysis
All continuous variables were analyzed with SPSS statistical software
package (Chicago, IL, USA). Bonferroni’s correction was applied for
multiple testing where appropriate.
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